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ABSTRACT
Medication-Related Osteonecrosis of the Jaw (MRONJ) therapy remains an unresolved problem. The proposed 
conservative and surgical treatment regimens are associated to contradictory success rates. Surgical approach 
with Er:YAG laser is associated to significant better results compared to medical treatment and traditional surgical 
approaches. Objective: To describe a new surgical approach that couples the advantages of the Er:YAG laser and the 
usefulness of the AF in highlighting surgical margins. One of the difficulties encountered during surgical removal 
of a MRONJ is the precise individuation of necrotic bone margins. Case Report: A case of Stage III mandibular 
osteonecrosis treated with a new surgical approach is presented. The aim is to describe an auto-fluorescence (AF) 
guided surgical approach performed with Er:YAG laser and Nd:YAG Low Level Laser Therapy (LLLT). After one 
month of follow-up, the complete mucosal healing was evident and symptoms was unobserved. Such a technique 
allowed a highly accurate and minimally invasive approach through the selective ablation of the non-/hypo-
fluorescent areas. Conclusion: Taking into account the advantages of laser therapy and the possible effectiveness 
of the AF in highlighting surgical margins, this approach would probably achieve excellent outcomes.
INTRODUCTION
Bisphosphonates-related osteonecrosis of the jaws 
(BRONJ) was defined in 2007 as an area of exposed 
bone in the maxillofacial region that does not heal 
within eight weeks after identification by a health care 
provider in a patient who received bisphosphonates 
therapy (BPT) and had not received radiation therapy 
to the craniofacial region.1,2
In order to accommodate the growing number of 
osteonecrosis cases associated with other anti-
resorptive and anti-angiogenic therapies, the American 
Association of Oral and Maxillofacial Surgeons 
(AAOMS) with a Position Paper in May 2014, changed 
the term in “Medication-Related Osteonecrosis of the 
Jaws” (MRONJ).3 
According to the new definition, a patient may be 
considered affected with MRONJ if all the following 
features are present: (1) current or previous treatment 
with anti-resorptive or anti-angiogenic agents; (2) 
exposed bone or bone that can be probed through an 
intraoral or extraoral fistula(e) in the maxillofacial 
region that has persisted for more than eight weeks; 
and (3) no history of radiation therapy to the jaws or 
obvious metastatic disease to the jaws.
To the best of our knowledge, there is no agreement on 
the management of such disorder and the success rates 
related to the different proposed protocols are very 
different and sometimes controversial.4,5
Many different therapeutic approaches have been 
reported such as anti-microbial rinses, antibiotics, 
Low Level Laser Therapy (LLLT), local debridement 
and surgical resection performed through different 
devices, or a combination of these two treatments. As 
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rates (HR) for nonsurgical approaches were 33% in 
Stage 1,24% in Stage 2 and 0% in Stage 3; HR for 
conservative surgical approaches were 72% in Stage 1, 
79% in Stage 2, and 27% in Stage 3; HR for extensive 
surgical approaches were 89% in Stage 0, 87% in 
Stage 1, 96% in Stage 2, and 81% in Stage 3 and 100% 
in Stage 1, 83% in Stage 2, 100% in Stage 3 for laser 
surgical approaches performed through Er:YAG and 
Er, Cr: YSGG lasers.6 
One of the most frequent difficulty encountered 
during the surgical removal of MRONJ is the precise 
individuation of necrotic bone margins, usually based 
on vascularization, colour and texture of the bone.10,11 
Some authors proposed the use of f luorescence 
tetracycline-induced in order to discriminate necrotic 
from viable bone. Due to its affinity to calcium, 
tetracycline is incorporated into the remodelling and 
apposition areas of the bone.12,13 It is then incorporated 
into viable but not into necrotic bone and can be 
visualized by an excitation light of 390 to 430 nm.14,15 
Ristow and Pautke in a recent technical note suggested 
that even in the absence of tetracycline labelling, the 
vital bone could be highlighted on the basis of its Auto-
Fluorescence (AF). Necrotic bone which is lost AF, 
appears very dark.16 This condition is possibly caused 
by alterations in the extracellular calcified osteoid 
matrix or in the bone cells of the necrotic tissue, but 
the specific mechanism has not yet been investigated.16
The aim of this paper is to describe a new surgical 
approach that couples the advantages of the Er:YAG 
laser and the usefulness of the AF in highlighting 
surgical margins.
CASE REPORT
A 65-year old female patient was affected by 
osteoporosis for which she received 84 doses im of 
Alendronic acid. The patient was diagnosed with a 
Stage 2 non-exposed osteonecrosis (according to the 
AAOMS 2014 staging system) on the right mandible 
(Figure 1). Dental anamnesis revealed the extraction of 
the premolars and the first molar in the same area four 
months before. Computed tomography (CT) scans and 
the 3D reconstruction showed a necrosis involving the 
vestibular and lingual plates (Figure 2A and B).
Surgical technique
The surgical treatment was performed under local 
anaesthesia. Antibiotic therapy with amoxicillin 
(2 gram/day) and metronidazole (1 gram/day) was 
administered from three days before to three weeks 
after intervention. No preoperative tetracycline 
labelling was performed. 
After mucoperiosteal flap was performed for affected 
bone exposure, the VELscopeTM (LED Medical 
Figure 1. Intra-operative view showing a non-exposed stage 
II osteonecrosis
Figure 2. Computed Tomography (CT) scan (A) and 3D 
reconstruction (B) showing an osteonecrosis that involve 
vestibular and lingual plates
reported in recent reviews, the success rate for surgical 
approaches are approximately 80%.6,7 Particularly, 
results obtained with Er:YAG laser-assisted surgical 
approaches are significantly better than those obtained 
through traditional surgery.8,9 
It is worthy to mention here that Rupel et al. in a 
systematic review had reported complete healing 
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Figure 3. A. Clinical photograph of the mucoperiosteal flap of the necrotic area; B. Visualization of  the mandibular bone 
using VELscopeTM (LED Medical Diagnostics Inc., Barnaby, Canada) showed no or only pale AF
Figure 4. Surgical field after mucoperiosteal flap elevation: A) necrotic bone B) Auto-fluorescence (AF) image showing 
hypo-fluorescent (dark) area
Figure 5. 5A,B. Clinical photograph and its AF visualization of the vestibular surface of the removed bone; 5B,C. Clinical 
photograph and its AF visualization of the lingual surface of the removed bone showed hyper fluorescent borders
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Diagnostics Inc., Barnaby, Canada) system was used 
to induce and visualize AF of the mandibular bone. It 
was evident that necrotic bone areas showed no or only 
pale AF (Figure 3A and B). Osteotomy was performed 
through Lindeman bur (Figure 4A and B).
After the removal of the necrotic bone block, AF 
visualization was used to guide the marginal bone 
osteoplasty (Figure 5). A traditional ball-shaped bur 
was used to remove sharp angles of the bone due to its 
minimum effect on the soft tissues.
According to the AF image obtained after osteoplasy, 
Er:YAG laser (Fidelis Plus®, Fotona - Slovenia) 
(Parameters: 300 mJ , 30 Hz, fluence of 60 J/cm2) 
was used for the vaporization of necrotic bone and for 
the detection of healthy bone (Figure 6).  This laser is 
useful in the removal of additional minimal bone after 
osteoplasty. Its action produces micro-spots on the bone 
surface for  vascularization and promoting healing and 
attachment of the soft tissue.25,26 
Moreover, through the minimally invasive action 
typical of this device, it is possible to act in the areas 
where non-fluorescence or hypo-fluorescence has been 
displayed.
The patient received an intra-operative irrigations 
with povidone iodine solution 10% and application of 
low level laser therapy (LLLT) (Nd:YAG laser, 1064 
nm, Fidelis Plus, Fotona®, Slovenia – power: 1.25 W; 
frequency: 15 Hz; diameter of the fibre: 320 μm) which 
was administered in non-focused mode, at 2 mm of 
distance from the tissues for 1 minute (power density: 
1562.5 W/cm2, fluence 7 J/cm2), five times. A tension-
free wound closure was achieved using continuous 
locked suture. The patient received weekly applications 
of LLLT for three weeks after intervention.
After one month, the complete mucosal healing was 
evident and there was no symptom observed (Figure 7). 
DISCUSSION
The identification of necrotic bone margins during 
osteonecrosis removal is a major difficulty for surgeons. 
Until now detection of necrosis has been solely based on 
radiological diagnostic images (e.g. CT scans, nuclear 
magnetic resonance), and on subjective parameters 
including the colour, texture and bleeding of the 
affected bone.19,20 Some studies reported that bone 
bleeding is not always correlated with histological 
findings of vital bone.5
The VELscopeTM device is a non-invasive tool designed 
as a first level diagnostic aid for increasing the 
diagnostic accuracy (DA) and enhance the specificity 
(SP) and sensitivity (SE) of the conventional oral 
examination in detecting early mucosal changes. 
VELscopeTM emits light in the blue spectrum (400-460 
nm) that excites natural fluochromes located within 
the epithelium and the submucosa. Fluochromes of the 
normal tissues show an AF in the range of the green 
colour; while displastic tissues associated with a loss 
of autofluorescence (LAF), appear dark in contrast to 
the surrounding area.21,22
A similar effect of LAF has been recently shown in 
necrotic bone.13,16 Ristow and Pautke speculated that 
such a fluorescence could be caused by alterations in 
the extracellular calcified osteoid matrix or in the bone 
cells.16 In the present observation, viable bone seems 
to emit a very bright AF, in contrast, a LAF seems 
to be present in areas of necrotic bone in patients 
affected with MRONJ. Consequently, Direct Visual 
Intra-operative Fluorescence Examination (DVIFE) 
seems to be a suitable guide to visualize necrotic 
bone during surgical debridement/resection. DVIFE 
as a guide to detect surgical margins of MRONJ is 
not invasive, easy to apply and independent from the 
subjective impression of the surgeon differently from 
the analysis of the clinical appearance of bone and 
radiological features. 
Figure 6. Er:YAG laser evaporation generates bone micro-
perforations in order to stimulate vascularization and 
promote healing and attachment of the soft tissue
Figure 7. Clinical photograph at one month after surgery 
showed complete mucosal healing
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The VELscopeTM DVIFE uses the AF principles and 
therefore pre-operative administration of tetracyclines, 
as proposed by some researcher, is not necessary. Due 
to its affinity to calcium, tetracycline is incorporated 
into the remodelling and apposition areas of bone. 
Therefore, it is incorporated into viable but not into 
necrotic bone and can be visualized using an excitation 
light of 390 to 430nm.23 Such f luorescence is not 
the AF from the bone but apparently it comes from 
tetracycline.
The surgical technique described in this paper 
associates the usefulness of the AF in highlighting 
surgical margins with the advantages of the Er:YAG 
laser. The Er:YAG laser beam (wavelength: 2.940nm) 
is highly absorbed by major components of bone, 
such as organic matrix and inorganic calcium salts. 
Er:YAG laser is used with distilled water irrigation 
system and air spray. It does not produce coagulation 
or carbonization. Such feature reduces the thermal 
damage on bone and the adjacent tissue. Each spot of 
the laser induces a vaporization of 0.1mm of tissue, 
achieving a gradual and safe ablation of the necrotic 
areas until reaching healthy bleeding bone. Particularly, 
the minimally invasive technique of bone evaporation 
is used to create micro-perforations in order to 
stimulate new vascularization and promote healing and 
attachment of the soft tissue on bone.17, 18
The association of the Er:YAG laser and the AF is 
highly useful in the removal of additional minimal 
necrotic bone after osteoplasty. It is possible to apply 
laser evaporation in the areas where non-fluorescence 
or hypo-fluorescence has been displayed. Moreover, 
biological advantages of Er:YAG surgery, such as 
bactericidal and biostimulative actions are valuable 
points in MRONJ surgery.17,18  
These properties are further enhanced by Nd:YAG 
LLLT that causes a bio-modulation of soft and hard 
tissues consisting of different effects, particularly 
anti-inf lammatory, bio-stimulating, anti-bacterial 
and analgesic.24 The bio-stimulating effect acts on the 
immune system and on the collagen tissue, increases 
proliferation and activity of fibroblasts, enhances 
cellular turnover on the epithelial tissue and ameliorate 
proliferation and activity of osteoblasts.9,10 The anti-
inflammatory effect is achieved by the increase of 
the microcirculation, the reduction of the oedema 
and by the suppressed production of prostaglandins, 
interleukin-1 (IL-1) and tumour necrosis factor-alpha 
(TNF-α).24 The analgesic effect is achieved through 
two mechanisms: indirect mechanism associated to the 
anti-inflammatory effects, and one direct mechanism 
against the nervous system. Particularly, the laser 
causes a hyperpolarization of the axonal membrane 
blocking the passage of the nervous impulse.24  All these 
features help to promote healing of bone and soft tissue 
and to improve the postoperative course and patient’s 
quality of life.
CONCLUSION
This case report shows that Er:YAG laser therapy has 
more biological advantages compared to conventional 
surgery that would allow the operator to achieve 
excellent outcomes for the patient healing process.
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